Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome‐Wide Association Meta‐Analysis Followed by Mendelian Randomization
Arthritis & Rheumatology · 2023
DOI: 10.1002/art.42538 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von Jie Zheng und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong Universit…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Atherosclerosis, Myocardial Infarction, Hypertension. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, NHLBI NIH HHS.
Abstract (Originalsprache)
Objective
In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors.
Methods
A genome‐wide association study meta‐analysis was performed of circulating sclerostin levels in 33,961 European individuals. Mendelian randomization (MR) was used to predict the causal effects of sclerostin lowering on 15 atherosclerosis‐related diseases and risk factors.
Results
We found that 18 conditionally independent variants were associated with circulating sclerostin. Of these, 1 cis signal in SOST and 3 trans signals in B4GALNT3 , RIN3 , and SERPINA1 regions showed directionally opposite signals for sclerostin levels and estimated bone mineral density. Variants with these 4 regions were selected as genetic instruments. MR using 5 correlated cis ‐SNPs suggested that lower sclerostin increased the risk of type 2 diabetes mellitus (DM) (odds ratio [OR] 1.32 [95% confidence interval (95% CI) 1.03–1.69]) and myocardial infarction (MI) (OR 1.35 [95% CI 1.01–1.79]); sclerostin lowering was also suggested to increase the extent of coronary artery calcification (CAC) (β = 0.24 [95% CI 0.02–0.45]). MR using both cis and trans instruments suggested that lower sclerostin increased hypertension risk (OR 1.09 [95% CI 1.04–1.15]), but otherwise had attenuated effects.
Conclusion
This study provides genetic evidence to suggest that lower levels of sclerostin may increase the risk of hypertension, type 2 DM, MI, and the extent of CAC. Taken together, these findings underscore the requirement for strategies to mitigate potential adverse effects of romosozumab treatment on atherosclerosis and its related risk factors. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, and Shanghai National Clinical…
- MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
- MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK, and Computational Medicine, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Be…
- Department of Neurology, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
- Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts.
- MRC IEU, Bristol Medical School, University of Bristol, Bristol, UK.
ORCID-Profile: Jie Zheng, Michelle S Yau, April E Hartley, Monika Frysz, Vid Prijatelj, Hubert Scharnagl, Eleftheria Zeggini
Förderung
- Wellcome Trust
- Medical Research Council
- NHLBI NIH HHS
- NIH HHS
- NIDDK NIH HHS
- NIAMS NIH HHS
- European Research Area Network on Cardiovascular Diseases
- National Heart, Lung, and Blood Institute
Zitieren
APA
Zheng, J., Wheeler, E., Pietzner, M., Andlauer, T. F. M., Yau, M. S., Hartley, A. E., Brumpton, B. M., Rasheed, H., Kemp, J. P., Frysz, M., Robinson, J., Reppe, S., Prijatelj, V., Gautvik, K. M., Falk, L., Maerz, W., Gergei, I., Peyser, P. A., Kavousi, M., …, & Tobias, J. H. (2023). Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome‐Wide Association Meta‐Analysis Followed by Mendelian Randomization. Arthritis & Rheumatology. https://doi.org/10.1002/art.42538
Vancouver
Zheng J, Wheeler E, Pietzner M, Andlauer TFM, Yau MS, Hartley AE, et al. Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome‐Wide Association Meta‐Analysis Followed by Mendelian Randomization. Arthritis & Rheumatology. 2023. doi:10.1002/art.42538
BibTeX
@article{Zheng2023,
author = {Zheng, Jie and Wheeler, Eleanor and Pietzner, Maik and Andlauer, Till F M and Yau, Michelle S and Hartley, April E and Brumpton, Ben Michael and Rasheed, Humaira and Kemp, John P and Frysz, Monika and Robinson, Jamie and Reppe, Sjur and Prijatelj, Vid and Gautvik, Kaare M and Falk, Louise and Maerz, Winfried and Gergei, Ingrid and Peyser, Patricia A and Kavousi, Maryam and de Vries, Paul S and Miller, Clint L and Bos, Maxime and van der Laan, Sander W and Malhotra, Rajeev and Herrmann, Markus and Scharnagl, Hubert and Kleber, Marcus and Dedoussis, George and Zeggini, Eleftheria and Nethander, Maria and Ohlsson, Claes and Lorentzon, Mattias and Wareham, Nick and Langenberg, Claudia and Holmes, Michael V and Davey Smith, George and Tobias, Jonathan H},
title = {Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome‐Wide Association Meta‐Analysis Followed by Mendelian Randomization},
journal = {Arthritis & Rheumatology},
year = {2023},
doi = {10.1002/art.42538}
}
EUVIMED